Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix files patent infringement lawsuit against Novel Laboratories
Salix has an exclusive license to the patent protecting Osmoprep from CDC III, for commercialization of Osmoprep in the US. The lawsuit is in response to an abbreviated
Salix has an exclusive license to the patent protecting Osmoprep from CDC III, for commercialization of Osmoprep in the US. The lawsuit is in response to an abbreviated
Dr Arlen will initially focus on the clinical development program for the company’s novel monoclonal antibody, NPC-1C, which is intended for the treatment of pancreatic cancer. In addition,
The series C round was led by new investor Nomura phase4 Ventures. New investor Westfield Capital Management and existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners,
The application to the FDA follows the completion of a randomized, parallel-group, open-label, multicenter Phase III clinical trial that evaluated time to progression (TTP) of the disease with
The compounds arise from Asterand’s R99 development program. They are selective, small molecule prostaglandin receptor agonists that have been shown in preclinical studies to be effective in reducing
The purpose of this multi-center, first-time-in-human, Phase I trial is to enroll patients with advanced solid tumors who have failed standard therapy. Patients will receive four weekly doses
The double-blind, placebo-controlled trial included four groups of 10 subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. After a 28-day
Pursuant to the letter of intent (LOI), Mikhail Kantius will join Boveran Diagnostics as the company’s chief pathologist and director of lab operations and business development for pathology
The company has also announced several recent appointments to the Zosano leadership team, including Don Brown, COO and president; John Vuko, executive vice president and CFO; Beth Piper,
The appearance of a drug on this list does not mean that the FDA has concluded that the drug has the listed risk, or that FDA has identified